Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | IKBKB | O14920 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.54 |
| ▸ | TUBB | P07437 | 6/20 | 0.54 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.54 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.54 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.54 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.54 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.54 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.54 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.54 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.54 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089054 | 0.87 | IKBKB (0.64) | MAPTKDM4EIKBKBTUBB4ATUBB | |
| SCHEMBL4082672 | 0.87 | TUBB4A (0.55) | MAPTKDM4ENPC1IKBKBRAB9A | |
| SCHEMBL15741576 | 0.87 | MAPT (0.67) | MAPTKDM4ENPC1IKBKBRAB9A | |
| SCHEMBL4088214 | 0.83 | TUBB4A (0.63) | MAPTKDM4ENPC1IKBKBRAB9A | |
| SCHEMBL30702063 | 0.83 | TUBB4A (0.63) | MAPTKDM4ENPC1IKBKBRAB9A | |
| SCHEMBL23452099 | 0.83 | IKBKB (0.62) | MAPTKDM4EIKBKBL3MBTL1APP | |
| SCHEMBL16689466 | 0.81 | GAA (0.66) | MAPTKDM4EIKBKBRAB9ATUBB4A | |
| SCHEMBL431794 | 0.80 | MAPT (0.74) | MAPTKDM4ENPC1IKBKBRAB9A | |
| Hydrochloric Acid SCHEMBL8864118 | 0.78 | MAPT (0.72) | MAPTKDM4ENPC1IKBKBRAB9A | |
| SCHEMBL1383955 | 0.76 | IKBKB (0.82) | KDM4ENPC1IKBKBRAB9AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2009-07-16 | — | — | US | disclosed |
| US-7358376-B2 | Substituted Thiophene compounds | ASTRAZENECA AB (SE) | 2008-04-15 | — | — | US | disclosed |
| EP-1261600-B1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| EP-1261600-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020107252-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2002-08-08 | — | — | US | disclosed |
| WO-2001058890-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181962-A1 | Substituted thiophene compounds | ABCG2, SULT1E1, TPMT | MAPT 2469/4885KDM4E 652/4885NPC1 1559/4885 |
| US-20020107252-A1 | Novel Compounds | UGT1A1, CYP1B1, CYP1A1 | MAPT 2580/4885KDM4E 1332/4885NPC1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.